Research powered investment banking
Home
Research
Companies
Find Alpha
Themes
Top Picks
Premium
Transactions
Events
Redeye
At a Glance
Our Culture
Investor Services
Corporate Broking
Certified Adviser
Corporate Finance
Newsroom
The Team
Careers
FAQ
Governance
Members network
Community
sign in
Home
research
Companies
Find Alpha
Themes
Top Picks
Transactions
Events
redeye
About
At a Glance
Our Culture
Investor Services
Corporate Broking
Certified Adviser
Corporate Finance
Newsroom
The Team
Careers
FAQ
Governance
Community
  • POSTS

Member profile

My Profile expand-item-icon-hover New Post

frallan

  • Blog posts

Inhalation Sciences

FR
frallan

2020-11-23
0 comments

Lungforskning kommer att öka avsevärt p.g.a. Covid-19

Inhalation Sciences med ett rekordår bakom sig växlar upp för lönsamhet

FR
frallan

2020-02-11
0 comments

Bygger upp verksamheten att uppnå klinisk godkännande för Preciseinhale, samt underbyggande lönsamhet för 2020. Börsvärde 36 miljoner kr exklusive Ziccum

Oncology Venture - an unpolished diamant?

FR
frallan

2019-04-23
0 comments

A company full of triggers, with six clinical drug candidates

Oncology Venture Sweden

Oncology Venture

FR
frallan

2018-10-19
0 comments

Vad har hänt sedan Oncology Venture & Medical Prognosis Institute sammanslogs

Oncology Venture Sweden

Redeye community rules

The Redeye community members are responsible for their content. As a reader, you’re encouraged to critically analyze the content and do your own research. Before posting or commenting, please review our Rules & Guidelines

Top posts last week

  • Prostalund - Nu en game-changer på en mångmiljard marknad 2021-01-19 appelbrand
  • Bubblan ingen vill spräcka 2021-01-17 labull
  • Laddstationsgiganten EVBOX kommer till börsen via merger med tickern TPGY 2021-01-06 Ossomaki


Top authors last week

  • AP
    appelbrand  
  • LA
    labull  
  • OS
    Ossomaki  
  • Office
  • Mäster Samuelsgatan 42, 10th floor
  • Box 7141, 103 87
  • Stockholm, Sweden
  • info@redeye.se
  • +46 (0)8 545 013 30
  • Services
  • Home
  • Research
  • Transactions
  • Events
  • Redeye
  • Community
  • Members Home
  • Premium
  • Legal
  • Terms and conditions (Swedish)
  • Terms of membership (Swedish)
  • Terms and conditions - Advisory (Swedish)
  • Terms and conditions - Advisory (English)
  • Integrity Policy (Swedish)
  • Disclaimer (Swedish)
  • Governance
  • Follow
  • Twitter
  • Facebook
  • LinkedIn
  • Redeye
  • At a Glance
  • Our Culture
  • Investor Services
  • Corporate Broking
  • Corporate Finance
  • Newsroom
  • The Team
  • Careers
  • FAQ

© All rights reserved. Redeye AB is authorised and regulated by the Swedish Financial Supervisory Authority, Finansinspektionen. 2021